Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
It is widely used in the food industry as a sweetener and humectant and in pharmaceutical formulations
Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026
Open Medicine, 18 (1), Article 20230692
MT received lecture fees from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sumitomo, and Mitsubishi Tanabe and received subsidies from Super Light Water, TAKAGI, Roche DC, and LifeScan
US$ 20.11
US$ 24.74
US$ 21.02
US$ 23.57
US$ 23.77
US$ 26.10
)
